中邮证券指出，我国核药行业上游核素原料进口依赖度高，但随着国内技术突破和产能投放，主要同位 素自主供应能力有望增强。核药监管严格，具备高壁垒，中国同辐和东诚药业在中游生产和流通领域具 备先发优势，核药房布局领先。RDC药物兴起吸引多家企业入局，目前国内尚无RDC产品获批， Pluvicto有望今明年上市。我国核医学应用水平与发达国家差距显著，但政策支持推动行业发展，《医 用同位素中长期发展规划》等文件促进规范发展，预计未来五年核药市场规模复合增速超20%，2030年 达260亿元。核药在精准治疗领域具备诊疗一体化优势，全球核医学市场预计2033年达314.4亿美元，治 疗用核药将占据主导地位。医疗资源配置增加和支付端政策支持有望提升核药普及度，行业迎来快速发 展阶段。 消息面上，2025年7月10日，成都高新区医疗器械创新转化协会推动区内企业青蓝集创医疗设备获得成 都银行千万级授信，专项用于产线拓展及技术研发；同日，安必平宣布其HPV核酸检测试剂盒获国家药 监局颁发的医疗器械注册证，可检测18种高危型HPV并分型，进一步扩充肿瘤筛查领域布局；此外，国 家药监局数据显示，2025年上半年我国批准创新医疗器械45 ...

注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参考，不 构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险等级相 匹配的产品。基金有风险，投资需谨慎。 光大证券指出，国家药监局发布公告支持高端医疗器械创新发展，医用机器人、高端医学影像设备、人 工智能医疗器械和新型生物材料医疗器械等是塑造医疗器械新质生产力的关键领域。创新医疗器械产品 有望在政策扶持下更快实现商业化落地，文件要求通过快速程序推动高端医疗器械急需标准立项，预计 后续相关政策将持续落地，从产品设计开发到生产过程质量控制、上市后监管等全方位标准体系将逐步 健全。此外，文件支持高端医疗器械企业"出海"发展，有望推动行业规范化、标准化、国际化发展，研 发实力强劲、产品规模化领先、出海战略领先的龙头企业有望获益。从支付视角看，医药产业内看好院 内政策支持（创新药械、设备更新）、人民群众需求扩容（血制品、家用医疗器械、减肥药产业链）、 出海周期上行（肝素、呼吸道联检）三大方向。 创业板医药ETF国泰 ...

证券研究报告 2025 年 07 月 10 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 3493.05 | -0.13 | | 深证成指 | 10581.80 | -0.06 | | 创业板指 | 2184.67 | 0.16 | | 科创 50 | 983.11 | -0.89 | | 北证 50 | 1410.36 | -0.75 | | 沪深 300 | 3991.40 | -0.18 | A 股市场概览 | 类别 | 总市值 | 流通市 | 市盈率 | 市净率 | | --- | --- | --- | --- | --- | | | (亿元) | 值(亿元) | PE | PB | | 上证指数 | 678228 | 526969 | 12.48 | 1.30 | | 深证成指 | 231866 | 190602 | 20.63 | 2.18 | | 创业板指 | 61229 | 48653 | 28.63 | 3.97 | | 科创 50 | 34395 | 22851 | 53.40 | 4.14 | | 北证 ...

Core Viewpoint - Anbiping has received the Medical Device Registration Certificate for its HPV nucleic acid detection kit, which enhances its product offerings in the cervical cancer detection market [1] Group 1: Product Development - The HPV nucleic acid detection kit utilizes real-time fluorescence PCR method for qualitative detection of 18 high-risk HPV DNA types in cervical samples [1] - The product also includes subtype detection for HPV16 and HPV18, which are significant in cervical cancer diagnosis [1] Group 2: Market Expansion - The new product complements the existing HPV detection products of the company, thereby broadening its market presence in cervical cancer screening [1] - The acquisition of the registration certificate supports the company's strategic layout in the tumor screening and diagnosis sector [1]

磐升生物的硬核创新远不止于此。作为国家级专精特新"小巨人"企业，磐升生物开辟了"细胞再 生"的新赛道，其核心产品——具有完整生理功能的组织工程人工皮肤，实现了毛囊、神经、血管等复 杂结构的再生，技术水平全球领先，为再生医学开辟了全新路径。 精准诊断"隐形冠军" 深耕体外诊断领域近二十载的山东莱博生物科技有限公司，是这条创新链上不可或缺的一环。 莱博生物总经理助理吴冰介绍，其核心"利器"——丙型肝炎核心抗原检测试剂盒，不仅拥有国内独 家专利，填补了技术空白，其检测效能更可与"金标准"核酸检测比肩。 "操作简便、成本低，非常适用于大规模筛查。"吴冰强调。以此为核心，莱博生物向上游突破免疫 原料研制，向下游延伸至全自动化学发光免疫分析仪等设备开发，构筑了完整的诊断生态链。 "目前，企业已形成'核心原料+诊断试剂+检测设备'的全链条布局。"吴冰表示，未来，莱博生物还 将研发触角延伸至心血管、肿瘤标志物、激素检测等新领域，不断拓宽精准诊断的疆界，让创新成果惠 及更广阔市场。" 在济南磐升生物实验室里，一张小小的生物芯片正悄然改变着肿瘤早筛格局。不远处，莱博生物的 实验室里，拥有独家专利的丙型肝炎核心抗原检测试剂盒正在封 ...

Group 1 - Lin Yanglin, the chairman of Xinlicheng, has been placed under detention and is under investigation, which may impact investor confidence despite the company stating the matter is unrelated to its operations [1] - Weiming Pharmaceutical's stock will be suspended for one day due to its trial progress not meeting expectations and its subsidiary's inability to resume normal operations within three months, affecting performance expectations [2] - Tengsheng Bo Pharmaceutical has signed a licensing agreement with Health Yuan Group for the exclusive rights to research, develop, and commercialize BRII-693 in China, providing cash flow and enhancing market expectations [3] Group 2 - China Resources Double Crane announced a cash dividend of 3.71 yuan per 10 shares despite a decline in revenue and net profit, indicating strong cash flow and commitment to shareholders [4] - InnoTech's subsidiary has obtained long-term product certification for a flu detection kit, which is expected to enhance market competitiveness and potentially increase revenue [5]

Group 1 - The article discusses the results of the quality management system inspections for medical device registrations conducted in May 2025 by the Guangdong Provincial Drug Administration [2][6] - Various companies and their respective products were evaluated, with some passing the inspection while others required corrective actions [3][4] - The inspections included a range of medical devices such as disposable catheters, X-ray systems, and diagnostic kits, indicating a broad scope of the medical device industry in Guangdong [5][6] Group 2 - Companies like Shenzhen Mindray Biomedical Electronics and Siemens (Shenzhen) Magnetic Resonance Co., Ltd. were mentioned, highlighting their involvement in the medical device sector [4][6] - The inspection results show a mix of compliance and non-compliance, with several companies needing to implement corrective measures before receiving approval [3][5] - The article emphasizes the importance of quality management systems in ensuring the safety and efficacy of medical devices in the market [2][6]

证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2025-003 值得特别关注的是，公司在拥有 GMP 级别质量管理体系平台基础上， 结合细胞治疗药物生产规范，以严格的质量管理和药品级放行检测标准，已 成功开发超 50 款高质量的 GMP 级别产品，包括细胞因子、细胞激活用抗体 和磁珠、全能核酸酶以及 Cas 酶等，适用于 CGT 药物 CMC、商业化生产和 临床研究。公司还可提供用于临床前研究的 Premium (Pre-GMP) 级别原料， 助力客户实现从临床前开发到临床阶段的无缝过渡。另外，公司针对细胞治 疗应用进行针对性的蛋白结构设计，能够提供从基因合成、载体构建到蛋白 质表达、纯化的 GMP 级别蛋白的一站式开发服务。 问：公司在 ADC 领域的布局？ 抗体偶联药物（ADC）作为新一代抗癌免疫治疗药物的代表，其独特之 处在于将高靶向性的抗体与强大的化疗药物相结合。这种结合方式不仅能在 肿瘤细胞内部实现精准投药，有效避免化疗药物对正常细胞的伤害，还显著 减少治疗过程中的不良反应。鉴于 ADC 在肿瘤等疾病治疗中展现出的巨大 潜力，现已成为抗体药 ...

长江商报消息 ●长江商报记者 沈右荣 股价暴涨后，热景生物（688068.SH）的重要股东拟高位接力减持套现。 6月26日晚，热景生物披露股东减持计划。股东周锌拟在未来三个月内减持不超过公司180万股股份，即不超过公 司总股本的1.94%。 周锌是热景生物第二大股东，目前持股比为7.34%。 6月6日，热景生物披露，公司第三大股东青岛同程热景企业管理咨询合伙企业（有限合伙）（以下简称"同程热 景"）完成了一轮减持计划，其顶格减持了公司180万股股份，套现约2.14亿元。 同程热景是热景生物的员工持股平台，公司实际控制人林长青为其执行事务合伙人。 备受关注的是，两大股东接力减持背后，2024年9月以来，热景生物的股价大涨约5倍。 长江商报记者发现，2021年，也是因为股价暴涨后，股东周锌等高位精准减持。 热景生物的业绩与股价严重背离。2024年，公司亏损1.91亿元，今年一季度再亏2400万元。 自2023年以来，公司营业收入持续下滑，研发投入不断缩水。公司如何扭转不利局面？ 这次减持，周锌将是精准地定位在高位。 周锌此次披露减持计划时，热景生物的股价已经暴涨。 K线图显示，2024年9月23日，热景生物的收盘 ...

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. is undergoing scrutiny regarding its business performance and financial disclosures, particularly focusing on its main business segments and the reasons behind revenue and cost fluctuations in 2024 [1][2]. Business Overview - The company's main business includes molecular detection reagents, nucleic acid extraction reagents, nucleic acid preservation reagents, and testing services [1]. - In 2024, the sales volume of molecular detection reagents increased by 34%, while nucleic acid extraction reagents saw a decline of 15%, and nucleic acid preservation reagents surged by 67% [1]. Revenue and Sales Analysis - The revenue, sales volume, and price changes for various product types in 2024 are as follows: - Molecular detection reagents: Sales volume of 60,984.04 million units, revenue of 5,870.64 million yuan, and a price increase of 15.16% [3]. - Nucleic acid extraction reagents: Sales volume of 1,691.71 million units, revenue of 2,448.73 million yuan, with a price increase of 8.17% [4]. - Nucleic acid preservation reagents: Sales volume of 1,297.61 million units, revenue of 2,802.23 million yuan, but a price decrease of 24.07% [4]. Customer Segmentation - The customer base for molecular detection reagents primarily consists of industrial clients, with sales to this segment increasing by 11.78% in revenue [4]. - Sales to distributors decreased by 15.39%, indicating a competitive market environment affecting pricing and sales volume [4]. Market Dynamics - The overall increase in sales volume for molecular detection reagents and nucleic acid preservation reagents is attributed to the company's ongoing market expansion and new product development [7]. - The decline in sales volume for nucleic acid extraction reagents is linked to increased application of non-extraction testing technologies by industrial clients, leading to reduced demand [7]. Cost and Material Analysis - The increase in direct material costs outpaced revenue growth due to product upgrades and market promotion strategies, resulting in a 6.41% increase in direct materials compared to a 2.25% decline in sales revenue [8]. - The overall pricing pressure in the molecular detection market has contributed to the disparity between revenue growth and material cost increases [8]. Bad Debt and Financial Health - The company reported a significant increase in bad debt losses, amounting to 0.44 billion yuan, with a notable rise in single-item provisions for bad debts [9]. - The increase in bad debt is primarily due to delayed payments from government units and enterprises related to testing services during public health events [10]. Investment Activities - In March 2024, the company acquired a 51% stake in Shanghai Haoweitai for 12.75 million yuan, with the acquisition date net assets valued at 26 million yuan [11]. - The acquisition of Guangzhou Kangjian was justified by the strategic need to enhance local operations and expand service offerings in the molecular testing market [12][14].